Zolmitriptan
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Zolmitriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Zolmitriptan is a triptan (5-HT1B/1D receptor agonist) originally used for acute migraine treatment. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, but there are currently 0 clinical trials and 20 publications on migraine in general, none of which specifically address brainstem aura.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine disorder (migraine with or without aura) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| US Market Status | Cancelled only (no currently valid licenses in the data compiled for this report) |
| Number of NDAs | 11 authorizations in total (1 NDA, 10 ANDAs), all with cancelled status |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on the literature, zolmitriptan is a selective 5-HT1B/1D receptor agonist that acts both centrally and peripherally. Preclinical studies show it can inhibit trigeminovascular activation at both levels.
Migraine with brainstem aura is a subtype of migraine, so it shares the same underlying pathophysiology: trigeminovascular activation, CGRP release and cranial vasodilation. This supports biological plausibility.
There is an important caveat. Triptans have historically carried precautionary labeling, or been contraindicated, in brainstem aura (basilar-type migraine) because of the theoretical risk of vasoconstriction. This is therefore a close extension of the approved use, but it needs a dedicated safety assessment. The available literature covers migraine generally (acute treatment guidelines, menstrual and vestibular migraine, triptan reviews, preclinical pharmacology), not brainstem aura specifically.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25600718 | 2015 | Review | Headache | American Headache Society evidence assessment of drugs for acute migraine treatment in adults |
| 12083998 | 2002 | Review | Expert Opin Pharmacother | Placebo-controlled trials show zolmitriptan has good 2-hour response and pain-free rates and improves nausea, photophobia and phonophobia; onset within 45 minutes |
| 10473025 | 1999 | Review | Drugs | Zolmitriptan 2.5 and 5 mg has rapid onset and is significantly more effective than placebo in moderate to severe migraine |
| 22644173 | 2012 | Subgroup analysis of a randomized trial | Neurol Sci | Frovatriptan vs zolmitriptan in migraine with aura (only 18 patients in the subgroup) |
| 25916333 | 2015 | Meta-analysis | J Headache Pain | Frovatriptan compared with rizatriptan, zolmitriptan and almotriptan in migraine with aura; triptans may not work when taken during the aura phase |
| 17177580 | 2007 | Postmarketing surveillance | Clin Drug Investig | Effectiveness, tolerability and satisfaction with zolmitriptan 5 mg nasal spray in real-life practice |
| 9399012 | 1997 | Preclinical | Cephalalgia | Zolmitriptan is a central and peripheral 5-HT1B/1D agonist that inhibits trigeminovascular activation |
| 12864759 | 2003 | Clinical study | Headache | Transcranial Doppler blood flow velocity before and after oral zolmitriptan or sumatriptan |
| 16268666 | 2005 | Review | CNS Drugs | Triptans in menstrual migraine; no controlled-trial evidence that it is harder to treat |
| 22298171 | 2012 | Case report | Cardiol J | Zolmitriptan-induced acute myocardial infarction in a 45-year-old woman (safety signal) |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021450 | ZOMIG | Metered spray | Not available (status: cancelled) |
| ANDA205074 | Zolmitriptan | Orally disintegrating tablet | Not available (status: cancelled) |
| ANDA202890 | Zolmitriptan | Orally disintegrating tablet | Not available (status: cancelled) |
| ANDA201779 | Zolmitriptan | Film-coated tablet | Not available (status: cancelled) |
| ANDA204041 | Zolmitriptan | Tablet | Not available (status: cancelled) |
Only 5 of the 11 authorizations are shown. All 11 are listed as cancelled.
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): hypertension; coronary artery disease; myocardial infarction and myocardial ischemia; Prinzmetal angina; stroke, transient ischemic attack and cerebrovascular disorders; peripheral vascular disease and Raynaud disease; ischemic bowel disease; Wolff-Parkinson-White syndrome; hemiplegic migraine; kidney and liver disease. These need confirmation against the official package insert.
- Drug Interactions: 82 interactions were recorded. Those rated Major include:
- Serotonergic and 5-HT3 antagonist drugs: lorcaserin, dolasetron, palonosetron, ondansetron, granisetron
- Serotonergic anorectic agents: dexfenfluramine, fenfluramine, sibutramine
- Moderate-level interactions include cimetidine, morphine and obeticholic acid.
- Literature signal: a case report describes acute myocardial infarction associated with zolmitriptan.
- Gap: package insert warnings and contraindications were not available in the data compiled for this report, so label-based safety screening has not been done.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is biologically plausible because brainstem aura is a migraine subtype, but the evidence is at L4: no clinical trials, and no literature that specifically addresses brainstem aura. Triptans have historically carried precautions in this subtype because of vasoconstrictive risk, and the US licenses are all cancelled. Label-based safety data are also missing.
To proceed, the following is needed:
- FDA package insert warnings and contraindications, especially regarding brainstem aura and hemiplegic migraine
- Mechanism of action data (for example from DrugBank)
- A dedicated cardiovascular and cerebrovascular safety assessment for brainstem aura
- Clinical or observational data specific to brainstem aura
- Clarification of current US market status and available formulations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.